MiMedx Group, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2023. The interim financial statements are unaudited and should be read with the 2022 Form 10-K.
Business Context and Reporting Period
MiMedx develops and sells placental biologic products, primarily for wound care and surgical applications in the United States. The company operated through Wound & Surgical and Regenerative Medicine business units during the period. On June 20, 2023, MiMedx decided to disband Regenerative Medicine and suspend its knee osteoarthritis clinical trial program, focusing resources on Wound & Surgical.
Products are regulated by the FDA, and the company applies Current Good Tissue Practices and terminal sterilization processes. MiMedx also continues to pursue selected international opportunities, including sales in Japan.
Financial Performance and Key Metrics
| Metric | Q3 2023 | Q3 2022 | Change |
|---|---|---|---|
| Net sales | $81.7 million | $67.7 million | 20.7% increase |
| Gross profit | $66.9 million | $55.5 million | 20.6% increase |
| Gross margin | 81.9% | 82.0% | Roughly flat |
| Operating income (loss) | $10.8 million | $(7.1) million | Improved |
| Net income (loss) | $8.5 million | $(8.4) million | Improved |
| Net income (loss) available to common shareholders | $6.8 million | $(10.1) million | Improved |
| Diluted earnings (loss) per share | $0.06 | $(0.09) | Improved |
| Metric | Nine months 2023 | Nine months 2022 | Change |
|---|---|---|---|
| Net sales | $234.6 million | $193.5 million | 21.3% increase |
| Gross profit | $193.9 million | $159.5 million | 21.5% increase |
| Gross margin | 82.6% | 82.5% | Slight increase |
| Operating income (loss) | $10.2 million | $(26.0) million | Improved |
| Net income (loss) | $4.8 million | $(29.8) million | Improved |
| Net income (loss) available to common shareholders | $(0.4) million | $(34.7) million | Improved |
| Diluted earnings (loss) per share | approximately $(0.00) | $(0.31) | Improved |
- Q3 sales increased across all sites of service: Hospital sales rose 17.9% to $47.4 million, Private Office sales rose 17.3% to $23.0 million, and Other sales rose 43.7% to $11.4 million.
- Advanced Wound Care represented substantially all revenue, generating $81.6 million in Q3 and $234.1 million for the nine-month period. Section 351 revenue declined to $0.1 million in Q3 from $0.9 million in the prior-year quarter.
- Q3 SG&A declined 1.7% to $52.6 million, while research and development expense declined 46.7% to $3.2 million as the Regenerative Medicine wind-down reduced personnel and clinical trial spending.
- Nine-month restructuring expense was $3.5 million, including clinical trial asset impairments, contract wind-down costs and $0.5 million of goodwill impairment.
- Interest expense increased to $1.7 million in Q3 and $4.9 million for the nine months, primarily because of higher reference interest rates.
- Cash provided by operating activities was $16.5 million for the nine months, compared with cash used of $12.3 million in the prior-year period.
- Capital expenditures and other investing activity used $1.7 million during the nine months. Financing activities provided $0.4 million.
- Cash and cash equivalents were $81.2 million at September 30, 2023, compared with $66.0 million at December 31, 2022.
- Current assets were $154.5 million and current liabilities were $43.6 million, producing a reported current ratio of 3.5.
Debt, Liquidity and Capital Structure
- The senior secured Hayfin Term Loan had $50.0 million of principal outstanding and a net carrying value of $49.0 million at September 30, 2023. It matures June 30, 2025, with no scheduled principal payments before maturity.
- The loan carried a 12.3% interest rate at September 30, 2023, based on SOFR plus the applicable margin. MiMedx was in compliance with its financial covenants.
- Management stated that existing cash and cash generated from operations should be sufficient to meet obligations over the 12 months following the filing date, including product investment, regulatory expansion, clinical-trial wind-down costs and severance.
- Series B Preferred Stock had a balance-sheet carrying value of $92.5 million. Accumulated and unpaid dividends were $19.0 million and were not recorded as a liability because they had not been declared.
- The Series B Preferred Stock was convertible into approximately 30.9 million common shares at September 30, 2023, creating potential dilution.
Material Changes Versus the Prior Comparable Period
- Revenue growth and continued adoption of products launched in the second half of 2022 drove substantial improvement in operating results.
- MiMedx moved from a Q3 2022 operating loss of $7.1 million to operating income of $10.8 million and from a net loss of $8.4 million to net income of $8.5 million.
- Investigation, restatement and related expense declined to an immaterial amount in Q3 from $3.0 million, and declined 47.0% for the nine-month period.
- Research and development spending declined materially in Q3 following the Regenerative Medicine restructuring, although nine-month R&D expense remained modestly above the prior-year period because clinical-trial spending increased during the first half of 2023.
- Cash generation improved significantly, with $16.5 million of operating cash flow compared with negative $12.3 million in the prior-year period.
- On October 27, 2023, after the quarter end, MiMedx agreed to repurchase 5,000 Series B Preferred shares from Hayfin-affiliated holders for $9.5 million in cash.
Outlook, Commentary, Risks and Unusual Items
- Management’s strategy is to focus on Wound & Surgical to drive profitability and cash flow. Activities related to the Regenerative Medicine restructuring were expected to materially conclude in the fourth quarter of 2023.
- Management cited strong commercial execution, new customer additions and product uptake as key drivers of Q3 growth. It also noted uncertainty regarding Medicare reimbursement policy for Private Office billings.
- The company terminated the Nordic Agreement supporting the knee osteoarthritis clinical trial and remains responsible for certain services, non-cancelable obligations and regulatory obligations for enrolled participants.
- Restructuring charges included approximately $2.1 million of clinical-trial asset impairment, $0.8 million of contract termination and trial wind-down costs, $0.5 million of goodwill impairment, and $2.1 million of severance recognized in research and development expense.
- Interest-rate exposure remains material because the Term Loan is variable-rate and unhedged. A 100-basis-point change in SOFR, above the loan’s floor, would affect annualized interest expense by approximately $0.5 million.
- Legal matters include the Welker litigation, indemnification-related matters involving former executives and other ordinary-course claims. The company stated that it had not accrued potential losses for legal matters as of September 30, 2023, and that outcomes cannot be predicted.
- Forward-looking results remain subject to FDA and other regulatory requirements, reimbursement changes, product demand, tissue supply, competition, litigation, clinical-trial obligations and the company’s ability to maintain liquidity and comply with debt covenants.
- No material changes were reported to the risk factors in the 2022 Form 10-K. Management concluded that disclosure controls and procedures were effective at a reasonable assurance level.
Important Facts for Investors to Verify
- Whether Wound & Surgical revenue growth and high-80% gross margins are sustainable after the benefit from newer product launches and favorable volume trends.
- The amount and timing of remaining Regenerative Medicine wind-down, severance, clinical-trial and contract termination costs.
- The company’s ability to refinance or repay the $50.0 million Term Loan at its June 2025 maturity and the effect of continued high SOFR-based interest expense.
- The impact of the $9.5 million post-quarter-end Series B Preferred Stock repurchase on cash, preferred dividends and potential dilution.
- The potential dilution from approximately 30.9 million shares issuable upon conversion of Series B Preferred Stock, plus outstanding equity awards.
- Exposure to Medicare reimbursement uncertainty in the Private Office channel and the regulatory status of the company’s Section 351 and other products.
- Potential cash requirements or adverse outcomes from litigation, indemnification obligations and other contingencies, for which the filing does not provide a clear maximum exposure.